Epkinly gets a second-line follicular nod
And AbbVie and Genmab scoop their ASH presentation with new data.
FDA red and green lights: October 2025
Syndax’s Revuforj beats Kura in NPM1-mutated AML.
GSK’s trio of cancer discontinuations
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
Blenrep against the odds
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
